Innoviva Inc (INVA)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Pavel Raifeld
Employees:
5
2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE, CA 94005
6502389600

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.

Data derived from most recent annual or quarterly report
Market Cap 864.059 Million Shares Outstanding69.57 Million Avg 30-day Volume 568.831 Thousand
P/E Ratio3.8027 Dividend Yield0.0 EPS1.94
Price to Revenue2.9811 Debt to Equity0.8417 EBITDA308.038 Million
Price to Book Value1.7347 Operating Margin76.9905 Enterprise Value862.214 Million
Current Ratio2.774 EPS Growth0.051 Quick Ratio2.279
1 Yr BETA 0.5015 52-week High/Low 20.71 / 11.57 Profit Margin89.553
Operating Cash Flow Growth-16.9666 Altman Z-Score2.0808 Free Cash Flow to Firm 82.151 Million
Earnings Report2023-02-08

Are you looking for this stock instead?

View SEC Filings from INVA instead.

View recent insider trading info

Funds Holding INVA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding INVA

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K/A: filed on 2022-10-28:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-14:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-23:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-22:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-27:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-20:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2022-07-13:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-11:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-11:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    SRIVASTAVA SAPNA

    • Director
    0 2023-01-01 1

    ZHEN MARIANNE CHIEF ACCOUNTING OFFICER

    • Officer
    38,653 2022-11-18 5

    EDWARDS LARRY G. CEO OF LA JOLLA PHARMACEUTICAL

    • Officer
    0 2022-08-22 1

    RAIFELD PAVEL CHIEF EXECUTIVE OFFICER

    • Officer
    504,533 2022-04-29 1

    BICKERSTAFF GEORGE

    • Director
    147,207 2022-04-25 1

    HAIMOVITZ JULES

    • Director
    110,411 2022-04-25 1

    ODYSSEAS KOSTAS D

    • Director
    92,207 2022-04-25 1

    SCHLESINGER SARAH J.

    • Director
    98,211 2022-04-25 1

    DIPAOLO MARK

    • Director
    98,211 2022-04-25 1

    BIRX DEBORAH

    • Director
    52,489 2022-04-25 1

    GLAXOSMITHKLINE PLC

    • 10% Owner
    No longer subject to file 2021-05-20 0

    HULME GEOFFREY INTERIM PRINCIPAL EXEC OFFICER

    • Officer
    No longer subject to file 2020-05-20 0

    ABERCROMBIE GEORGE B SR. VP & CHIEF COMM. OFFICER

    • Officer
    285,479 2018-08-20 0

    WITEK THEODORE J. JR. SR. VP & CHIEF SCIENTIFIC OFF.

    • Officer
    247,767 2018-08-20 0

    DESPARBES ERIC SVP AND CFO

    • Officer
    373,081 2018-05-20 0

    AGUIAR MICHAEL W PRESIDENT & CHIEF EXEC OFFICER

    • Officer
    • Director
    980,907 2017-12-04 0

    FAERM MICHAEL E. SR VP & CHIEF BUSINESS OFFICER

    • Officer
    279,422 2017-11-20 0

    LEPORE PATRICK G

    • Director
    58,278 2017-04-20 0

    WALTRIP WILLIAM H

    • Director
    161,789 2017-04-20 0

    TYREE JAMES L

    • Director
    70,554 2017-04-20 0

    DUNCAN BARBARA GAYLE

    • Director
    52,318 2017-04-20 0

    FRIEDMAN CATHY

    • Director
    73,805 2017-04-20 0

    PEPE PAUL

    • Director
    73,805 2017-04-20 0

    KEARNEY TERRENCE C

    • Director
    37,083 2015-04-24 0

    BLUM LEONARD M SR VP, CHIEF COMM. OFFICER

    • Officer
    401,538 2014-08-20 0

    SHAFER BRADFORD J SR VP, GEN. COUNSEL, SECRETARY

    • Officer
    443,013 2014-08-20 0

    MAMMEN MATHAI SVP, RESEARCH & EARLY CLIN DEV

    • Officer
    334,040 2014-08-20 0

    LEE JUNNING SR. VP, TECHNICAL OPERATIONS

    • Officer
    262,198 2014-08-20 0

    WINNINGHAM RICK E

    • Director
    825,391 2014-08-15 0

    MALKIEL BURTON G

    • Director
    41,000 2014-05-22 0

    RINGROSE PETER S

    • Director
    36,000 2014-05-22 0

    YOUNG WILLIAM D

    • Director
    83,935 2014-05-22 0

    WHITESIDES GEORGE M

    • Director
    776,695 2014-05-22 0

    GUNDERSON ROBERT V JR

    • Director
    121,679 2014-05-22 0

    FORE HENRIETTA

    • Director
    33,000 2014-05-22 0

    LEVINE ARNOLD J

    • Director
    111,794 2014-03-21 0

    PASQUALONE FRANK SR. VICE PRESIDENT, OPERATIONS

    • Officer
    20,000 2014-01-23 0

    JONKER JEFFREY DAVID SENIOR VP, CORP. & BUS. DEV.

    • Officer
    15,000 2013-10-22 0

    BRINKLEY DAVID L HEAD OF BUSINESS DEV.

    • Officer
    48,749 2013-05-29 0

    AUNGER PAUL SECRETARY

    ADVISORS LLC

    • Officer
    • Director
    • 10% Owner
    28,097,122 2012-11-01 0

    DRAZAN JEFFREY M

    • Director
    33,465 2012-05-01 0

    INOVA TECHNOLOGY INC. PRESIDENT

    • Officer
    • Director
    35,700,884 2012-01-22 0

    VAGELOS P ROY

    • Director
    1,572,729 2009-12-23 0

    KITT MICHAEL SR. VICE PRESIDENT DEVELOPMENT

    • Officer
    32,738 2008-06-02 0

    HUMPHREY PATRICK PA EXECUTIVE VP RESEARCH

    • Officer
    85,954 2007-12-10 0

    AUNGER PAUL SECRETARY, TREASURER

    • Officer
    • Director
    • 10% Owner
    295,933,739 2007-05-21 0

    RADLY ADAM E CHIEF EXECUTIVE OFFICER

    • Officer
    568,938,076 2007-03-03 0

    MANDELBAUM JEFFREY

    • Director
    0 2006-12-11 0

    LOEWENTHAL RONN

    • Director
    21,613 2006-05-02 0

    KIM TAE HO

    • 10% Owner
    13,679,769 2006-01-20 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    INNOVIVA INC INVA 2023-01-26 22:15:03 UTC 4.0484 0.2716 2400000
    INNOVIVA INC INVA 2023-01-26 21:45:03 UTC 4.0484 0.2716 2400000
    INNOVIVA INC INVA 2023-01-26 21:15:04 UTC 4.0484 0.2716 2400000
    INNOVIVA INC INVA 2023-01-26 20:45:03 UTC 4.0484 0.2716 2400000
    INNOVIVA INC INVA 2023-01-26 20:15:04 UTC 4.0484 0.2716 2400000
    INNOVIVA INC INVA 2023-01-26 19:45:03 UTC 4.0484 0.2716 2300000
    INNOVIVA INC INVA 2023-01-26 19:15:04 UTC 4.0484 0.2716 2300000
    INNOVIVA INC INVA 2023-01-26 18:45:03 UTC 4.0492 0.2708 2300000
    INNOVIVA INC INVA 2023-01-26 18:15:04 UTC 4.0492 0.2708 2300000
    INNOVIVA INC INVA 2023-01-26 17:45:04 UTC 4.0492 0.2708 2300000
    INNOVIVA INC INVA 2023-01-26 17:15:04 UTC 4.0492 0.2708 2300000
    INNOVIVA INC INVA 2023-01-26 16:45:03 UTC 4.0492 0.2708 2300000
    INNOVIVA INC INVA 2023-01-26 16:15:04 UTC 4.0492 0.2708 2300000
    INNOVIVA INC INVA 2023-01-26 15:45:03 UTC 4.0492 0.2708 2200000
    INNOVIVA INC INVA 2023-01-26 15:15:04 UTC 4.0492 0.2708 2300000
    INNOVIVA INC INVA 2023-01-26 14:45:04 UTC 4.0695 0.2505 2200000
    INNOVIVA INC INVA 2023-01-26 14:15:03 UTC 4.0695 0.2505 2200000
    INNOVIVA INC INVA 2023-01-26 13:45:03 UTC 4.0695 0.2505 2200000
    INNOVIVA INC INVA 2023-01-26 13:15:04 UTC 4.0695 0.2505 2200000
    INNOVIVA INC INVA 2023-01-26 12:45:04 UTC 4.0695 0.2505 2200000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Index Plus All-Cap Fund INVA -1.0 shares, $-11.76 2020-03-31 N-PORT
    Franklin Alternative Strategies Funds- Franklin K2 Alternative Strategies Fund INVA -30174.0 shares, $-397089.84 2022-08-31 N-PORT
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund INVA -400.0 shares, $-4644.0 2022-09-30 N-PORT
    JNL Series Trust- JNL Multi-Manager Alternative Fund INVA -40729.0 shares, $-472863.69 2022-09-30 N-PORT
    AQR Funds- AQR Diversified Arbitrage Fund INVA -205528.0 shares, $-2386180.08 2022-09-30 N-PORT
    LAZARD FUNDS INC- Lazard Enhanced Opportunities Portfolio INVA -14605.0 shares, $-169564.05 2022-09-30 N-PORT
    VANGUARD MONTGOMERY FUNDS- VANGUARD MARKET NEUTRAL FUND INVA -357495.0 shares, $-4150516.95 2022-09-30 N-PORT
    Calamos Investment Trust/IL- Calamos Market Neutral Income Fund INVA -911100.0 shares, $-12354516.0 2022-10-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments